DiscoverFractals: Life Science ConversationsImaging the Invisible: Granzyme B and the Future of Immunotherapy Monitoring with Guest Dr. Ben Larimer
Imaging the Invisible: Granzyme B and the Future of Immunotherapy Monitoring with Guest Dr. Ben Larimer

Imaging the Invisible: Granzyme B and the Future of Immunotherapy Monitoring with Guest Dr. Ben Larimer

Update: 2025-06-11
Share

Description

As a scientist, innovator, and CEO of CytoSite BioPharma, Dr. Ben Larimer has reshaped how we think about imaging immune response in cancer. His work on Granzyme B PET imaging is unlocking unprecedented insights into whether—and where—immunotherapies are working inside the body.

In this episode of Fractals, Ben joins host Colin Miller to discuss:

  • The origins of Granzyme B imaging and what makes it a uniquely powerful imaging agent.
  • How CytoSite’s imaging agent revealed success in preclinical models—and sparked a new clinical path forward.
  • The balance between scientific innovation and real-world biotech execution.
  • Why PET imaging’s future depends on AI, cost reduction, and deeper diagnostic precision.

Tune into Fractals: Life Science Conversations wherever you get your podcasts—and contact Bracken to learn how we help imaging agents move from molecule to market.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Imaging the Invisible: Granzyme B and the Future of Immunotherapy Monitoring with Guest Dr. Ben Larimer

Imaging the Invisible: Granzyme B and the Future of Immunotherapy Monitoring with Guest Dr. Ben Larimer

The Bracken Group